99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy

Journal of Nuclear Medicine

Volumn 40, Issue 5, 1999, Pages 768-775

  Ramos Suzarte, Mayra ^a   Rodríguez, Nelson ^a   Oliva, Juan P ^a   Iznaga Escobar, Normando ^a,b   Perera, Alejandro ^a   Morales, Alejo ^a   Gonzalez, Niurka ^a   Cordero, Maria ^a   Torres, Leonel ^a   Pimentel, Gilmara ^a   Borrón, Mercedes ^a   González, Joaquín ^a   Torres, Olga ^a   Rodríguez, Teresita ^a   Pérez, Rolando ^a  

^a Medical Surgical Research Center   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Anti epidermal growth factor receptor antibody; Diagnostic efficacy; Epithelial tumors; Radioimmunoscintigraphy

Indexed keywords

EPIDERMAL GROWTH FACTOR; TECHNETIUM 99M; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; ANIMAL; IMAGE PROCESSING; IMMUNOLOGY; MIDDLE AGED; MOUSE; MULTICENTER STUDY; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION AND FORECASTING; RADIOIMMUNOASSAY; SAFETY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; PREDICTIVE VALUE OF TESTS; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SAFETY; SENSITIVITY AND SPECIFICITY; SODIUM PERTECHNETATE TC 99M; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032587872     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Sheryl L, Parker SI, Tong T, Bolden S, Wingo PA. Cancer statistics. Cancer J Clin, 1996;46:15-27.
2. Statistical Annual Report. National Statistical Direction. Cuba: Public Health Organization; 1996.
3. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancer. Br Med Bull. 1991;47:87-98.
4. Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, Christopher D. Differentiation or immune destruction. Two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res. 1994;54:1695-1701.
5. Macias A, De los Rios M, Pérez R, Skoog L, Lage A. Epidermal growth factor receptor (EGF-r) expression in human breast cancer. Interferon Biotechnol. 1989;6:143-153.
6. Fox SB, Smith K, Hollyer J, et al. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat. 1994;29:46-49.
7. Radinsky R, Risin S, Fan D, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res. 1995;1:9-31.
8. Fontanini G, Vignati S, Bigini D, et al. Epidermal growth factor receptor (EGF-R) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer. 1995;31A:178-183.
9. Ciardiello F, Tortora G, Bianco C, et al. Epidermal growth factor-related growth factors in human colorectal cancer. Forum Trends Exp Clin Med. 1995;5:281-291.
10. Zalutsky MR. Growth factor receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med. 1997;41:71-77.
11. Divgi CR, Welt S, Kris M, el al. Phase 1 and imaging trial of indium-111 labeled anti-HEGF-receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991;83:97-104.
12. 111In [abstract]. Proc Am Soc Clin Oncol. 1993;12:142A.
13. Dadpavar S, Krishna L, Miyamoto C, et al. Indium 111-labeled scintigraphy in the detection of malignant gliomas. Cancer. 1994;1(suppl):73.
14. Snelling L, Miyamoto CT, Bender H, et al. Epidermal growth factor receptor 425 monoclonal antibody radiolabeled with iodine 125 in the adjuvant treatment of high grade astrocytomas. Hybridoma. 1995;14:111-114.
15. Fernández A, Pérez R, Macías A, et al. Generation and primary characterization of monoclonal antibodies epidermal growth factor receptor [in Spanish]. Interferon Biotechnol. 1989;6:289-298.
16. Fernández A, Spitzer E, Pérez R, et al. A new monoclonal antibody for detection of HEGF-receptors in Western blots and paraffin-embedded tissue sections. J Cell Biochem. 1992;49:157-165.
17. Oliva JP, Osorio M, Pimentel G, et al. Detection of unknown brain metastasis using immunoscintigraphy with ior egf/r3 monoclonal antibody [in Spanish]. Rev Esp Med Nucl. 1997;16:321-323.
18. Rodríguez N, Torres O, Ramos M, et al. Diagnosis of epithelial tumor by immunoscintigraphy with ior egf/r3 monoclonal antibody [in Spanish] [abstract]. Rev Esp Med Nucl. 1995;14:285.
19. Iznaga-Escobar N, Torres LA, Morales A, et al. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy. J Nucl Med. 1998;39:15-23.
20. Iznaga-Escobar N, Torres LA, Morales A, et al. Technetium-99m-anti-epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part II. Pharmacokinetics and clearances. J Nucl Med. 1998;39:1918-1927.
21. Schwarz A, Steinstraber A. A novel approach to Tc-99m-labeled monoclonal antibodies [abstract]. J Nucl Med. 1987;28:721.
22. Iznaga-Escobar N, Morales A, Nuñez G. Micromethod for quantification of SH groups generated after reduction of monoclonal antibodies. Nucl Med Biol. 1996;23:641-644.
23. Morales A, Zayas F, Nunez G, Iznaga-Escobar N, Pérez N, Izquierdo JC. Technetium-99m direct radiolabeling of monoclonal antibody ior egf/r3. Nucl Med Biol. 1998;25:25-30.
24. Macias A, Pérez R, Lage A. Epidermal growth factor studies. II. Development of radioreceptor assay methods to detect picomolar quantities [in Spanish]. Interferon Biotechnol. 1985;2:115-127.
25. Modjtahedi H, Dean CJ. The receptor of EOF and its ligands: expression prognostic value and target for therapy to cancer. Int J Oncol. 1994;4:277-296.
26. 99mTc for immunoscintigraphy [in Spanish]. Rev Esp Med Nucl. 1995;14:10-17.
27. Abdel-Nabi H, Doerr RJ, Chan HW, Balu D, Schmether RF, Maguire RT. In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma. Safety, sensitivity and preliminary clinical results. Radiology. 1990;75:163-171.
28. Stasieki P, Kemshead JT, Westphal M, Delattre JY, Gropp P, Simane Z. The development of HAMA in glioma patients can be suppressed by administration of murine MAb in short time intervals [abstract]. Cancer Res. 1993;34:A2835.
29. Modjtahedi H, Hickish T, Nicolson M, et al. Phase I trial and tumor localization of the anti EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer. 1996;73:228-235.
30. Samsbury JRC, Nicholson S, August B, Farndon JR, Malcolm AJ, Harris AC. Epidermal growth factor receptor status of histological sub-types of breast cancer. Br J Cancer. 1998;58:458-460.
31. Yasui W, Sumayoshi H, Hata J, et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988;98:137-141.
32. Kaklamanis L, Gatter NC, Matense N, Harris AL. Interleukin-4 receptor and epidermal growth factor receptor in colorectal cancer. Br J Cancer. 1992;66:712-716.
33. Maurizi M, Scambia G, Benedetti P, et al. EGF R expression in primary laryngeal cancer: correlation with clinic-pathological features and prognostic significance. Int J Cancer. 1992;52:862-866.
34. Akslen LA, Myking AO, Salvensen H. et al. Prognostic impact of EGF-R in papillary thyroid carcinoma. Br J Cancer. 1993;68:808-812.
35. Rios AM, Macias A, Pérez R, Lage A, Soon L. Receptor for epidermal growth factor and estrogen as predictors of relapses in patients with mammary carcinoma. Anticancer Res. 1988;7:173-176.